Vaccines Business Pfizer Completes Acquisition of Baxter’s Marketed Vaccines
Pfizer announced that it has completed the acquisition of Baxter International´s portfolio of marketed vaccines, which consists of Neis Vac-C and FSME-Immun/Tico Vac. As previously reported, Pfizer also acquired a portion of Baxter’s facility in Orth, Austria, where these vaccines are manufactured.
New York/USA – “Neis Vac-C and FSME-Immun/Tico Vac are a strong fit with our vaccines business and this acquisition adds value, scale and depth to our existing portfolio of innovative vaccines,” said Susan Silbermann, president and general manager, Pfizer Vaccines. “These best-in-class products enable us to reach a broader population with vaccines that prevent infections from serious and often fatal diseases.”
Neis Vac-C is a vaccine that helps protect against meningitis caused by group C meningococci (Men C). This serious infection of the membrane covering the brain may be fatal in roughly 10 to 15 percent of patients and 30 percent to more than 50 percent of survivors may suffer from severe physical, social and mental damage. Men C is one of the most prevalent meningococcal serogroups in many parts of the world and vaccination with Neis Vac-C has been shown to be highly effective.
FSME-Immun/Tico Vac is a vaccine that helps protect against tick-borne encephalitis (TBE), an infection of the brain, which is transmitted by the bite of ticks infected with the TBE-virus. Every year, the TBE virus causes thousands of cases of neuroinvasive illness in humans across Europe and Asia and is a growing public health concern in Europe and other parts of the world. FSME-Immun/Tico Vac is approved in 30 countries and has been marketed for over 30 years with approximately 120 million doses produced since 1976.